tetano
Editor, Senior Moderator
Diagnosis (Berl)
. 2020 Jul 20;/j/dx.ahead-of-print/dx-2020-0078/dx-2020-0078.xml.
doi: 10.1515/dx-2020-0078. Online ahead of print.
COVID-19-associated coagulopathy
Massimo Franchini[SUP] 1 2 [/SUP], Giuseppe Marano[SUP] 1 [/SUP], Mario Cruciani[SUP] 1 3 [/SUP], Carlo Mengoli[SUP] 1 [/SUP], Ilaria Pati[SUP] 1 [/SUP], Francesca Masiello[SUP] 1 [/SUP], Eva Veropalumbo[SUP] 1 [/SUP], Simonetta Pupella[SUP] 1 [/SUP], Stefania Vaglio[SUP] 1 [/SUP], Giancarlo Maria Liumbruno[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized as a systemic disorder inducing a prothrombotic state. The molecular mechanisms underlying the hypercoagulable state seen in patients with COVID-19 is still incompletely understood, although it presumably involves the close link between inflammatory and hemostatic systems. The laboratory coagulation monitoring of severely ill COVID-19 patients is mandatory to identify those patients at increased thrombotic risk and to modulate thromboprophylaxis accordingly. In this review, we summarize the current understanding on the pathogenesis, epidemiology, clinical and laboratory features and management of coagulopathy associated with COVID-19.
Keywords: COVID-19; SARS-CoV-2; anticoagulant therapy; prophylaxis; thromboembolism; thrombosis.
. 2020 Jul 20;/j/dx.ahead-of-print/dx-2020-0078/dx-2020-0078.xml.
doi: 10.1515/dx-2020-0078. Online ahead of print.
COVID-19-associated coagulopathy
Massimo Franchini[SUP] 1 2 [/SUP], Giuseppe Marano[SUP] 1 [/SUP], Mario Cruciani[SUP] 1 3 [/SUP], Carlo Mengoli[SUP] 1 [/SUP], Ilaria Pati[SUP] 1 [/SUP], Francesca Masiello[SUP] 1 [/SUP], Eva Veropalumbo[SUP] 1 [/SUP], Simonetta Pupella[SUP] 1 [/SUP], Stefania Vaglio[SUP] 1 [/SUP], Giancarlo Maria Liumbruno[SUP] 1 [/SUP]
Affiliations
- PMID: 32683333
- DOI: 10.1515/dx-2020-0078
Abstract
Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been recently recognized as a systemic disorder inducing a prothrombotic state. The molecular mechanisms underlying the hypercoagulable state seen in patients with COVID-19 is still incompletely understood, although it presumably involves the close link between inflammatory and hemostatic systems. The laboratory coagulation monitoring of severely ill COVID-19 patients is mandatory to identify those patients at increased thrombotic risk and to modulate thromboprophylaxis accordingly. In this review, we summarize the current understanding on the pathogenesis, epidemiology, clinical and laboratory features and management of coagulopathy associated with COVID-19.
Keywords: COVID-19; SARS-CoV-2; anticoagulant therapy; prophylaxis; thromboembolism; thrombosis.